A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1023 participants.

Also called NCT06534411

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,023 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06534411
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Germany, Greece, Hungary, India, Israel, Poland, Romania, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06534411. Randomized; no masking; primary purpose treatment. Start 2024-11-05 (actual); primary completion 2026-06-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Acronym
REIMAGINE 5
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Cagrilintide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Tirzepatide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06534411
Content hash
d9db9a0aa358ea9cb7682687b62f0f7c5fef7139552abfd6633db87c0348a5f9